Six pharmacists got paid for medicine that never left the shelf - and a federal appeals court just upheld their convictions.
On June 12, 2026, the Sixth Circuit affirmed the convictions of four Michigan pharmacists who, with two others, billed insurers for prescriptions they never dispensed. The scheme ran for years across five pharmacies in Michigan and Ohio and cost the government roughly $13.2 million, a federal contractor estimated.
Here is how it worked, and why claims teams should care. When a pharmacy fills a prescription, it bills the patient's insurer through a middleman called a pharmacy benefit manager, or PBM. The PBM checks eligibility and authorizes payment. If the patient never picks up the medicine, the pharmacy is supposed to reverse the claim.
These pharmacists did the reverse of that. The court found they targeted patients who were noncompliant with their medications, held onto labels for prescriptions that would never be dispensed, and told staff not to process the cancellations. They kept the money. To drive up volume, they waived copays on costlier drugs like insulin, and at one store they billed for brand-name drugs after quietly swapping in the generic form.
The payoff was large. The court said the group made millions and drew thousands in monthly profit-sharing checks - and recounted that two of them, neither of whom is among the four appellants here, joked that no "legal" business made as much.
What undid them was the industry's own audit machinery. PBMs audited in-network pharmacies, collecting patient signatures and pulling wholesaler invoices to confirm the drugs were actually bought. The pharmacists often forged patient signatures to get past the signature checks, the court found. But the invoice comparison exposed large shortages: they had billed for more medication than they ever purchased.
A federal contractor, Qlarant, which holds a Medicare drug-integrity contract, ran its own invoice review and reached the same result across all five pharmacies. It put the loss at about $13.2 million.
The defendants challenged the expert testimony, the evidence the trial judge kept out, and their sentences. The panel turned all of it down. The trial court had sentenced Hamaed to 120 months, Fakhuri to 84, Ghussin to 65, and Abdelrazzaq to 24, with restitution running into the millions.
The lesson for carriers and PBMs is plain. Signature collection catches some fraud, but it can be faked. The wholesaler-invoice reconciliation is what surfaced the shortfall here - and it held up through trial, sentencing, and appeal.
